AFT PHARMACEUTICALS

AFT
End-of-day quote. End-of-day quote  - 01/15
5.21NZD -0.76%

AFT Pharmaceuticals : FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2020Opens in a new Window

11/18/2020 | 04:07pm

Working to improve your health

INVESTOR PRESENTATION NOVEMBER 2020

Investor presentation November 2020

Important Notice

This presentation has been prepared by AFT Pharmaceuticals Limited ("AFT"), to provide a general overview of the performance of AFT for the financial year ended 31 March 2020. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presentation should be read in conjunction with AFT's annual report, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.comand www.asx.com.au.

All amounts are disclosed in New Zealand dollars (NZ$) unless otherwise indicated. All references to FY20XX appearing in this presentation are to the financial year ending 31 March 20XX, unless otherwise indicated.

This presentation is not a recommendation, offer or invitation to acquire AFT's securities or other form of financial advice or disclosure document. While reasonable care has been taken in compiling this presentation, none of AFT nor its subsidiaries, directors, employees, agents or advisers (to the maximum extent permitted by law) gives any warranty or representation (express or implied) of the accuracy, completeness or reliability of the information contained in it nor takes any responsibility for it. The information in this presentation has not been and will not be independently verified or audited.

This presentation may contain certain forward-looking statements and comments about future events, including with respect to the financial condition, results, operations and business of AFT. These statements are based on management's current expectations, which may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and the actual events or results may differ materially and adversely from these statements.

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of future performance.

2

Investor presentation November 2020

H1 FY2021 financial highlights

21%

Increase in number of countries Maxigesic sold in to

34

9%

Increase in operating revenue from product sales to

$48.4m

38%

Decline in normalised operating profit1 to

$2.4m

(9% growth if adjusted for one off $1.7 million R&D credit in PY)

968% Increase in normalised net profit after tax to

$1.2m

$8.9m

(Used for stock build with Covid19 uncertainty)

$(2.7)m

Decrease in operating cash flow to

73%

Increase in shareholders equity to

$29.9m

3

1 FY20 normalised to exclude $9.8m gain on de-recognition of equity accounted investment and recognition of net assets acquired at fair value in a step acquisition

Revenue Growth

11%

0%

(16)%

(7)%

53% product sales growth

Investor presentation November 2020

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

AFT Pharmaceuticals Limited published this content on 19 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2020 21:06:01 UTC

© Publicnow 2021
Copier lien
All news about AFT PHARMACEUTICALS LIMITED
12/22
12/14
11/19
11/18
11/18